NASDAQ:AXSM Axsome Therapeutics Q2 2026 Earnings Report $212.74 +2.61 (+1.24%) Closing price 08/7/2026 04:00 PM EasternExtended Trading$211.84 -0.90 (-0.42%) As of 08/7/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Axsome Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.89Beat/MissN/AOne Year Ago EPSN/AAxsome Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$221.11 millionBeat/MissN/AYoY Revenue GrowthN/AAxsome Therapeutics Announcement DetailsQuarterQ2 2026Date8/10/2026TimeBefore Market OpensConference Call DateMonday, August 10, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Axsome Therapeutics Earnings HeadlinesHerriot Tabuteau Sells 45,004 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock24 minutes ago | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4% Following Analyst DowngradeAugust 5, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Axsome Therapeutics (AXSM) Expected to Release Quarterly Earnings on MondayAugust 3, 2026 | americanbankingnews.comMizuho Has Lowered Expectations for Axsome Therapeutics (NASDAQ:AXSM) Stock PriceAugust 2, 2026 | americanbankingnews.comAxsome’s Phase 3 Fibromyalgia Trial of AXS-14 Takes Shape: What Investors Should WatchJuly 24, 2026 | tipranks.comSee More Axsome Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Axsome Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Axsome Therapeutics and other key companies, straight to your email. Email Address About Axsome TherapeuticsAxsome Therapeutics (NASDAQ:AXSM) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes. Axsome’s pipeline includes several late-stage and approved product candidates. AXS-05, a first-in-class oral investigational therapy combining dextromethorphan and bupropion, received U.S. Food and Drug Administration (FDA) approval for the treatment of major depressive disorder in 2021 and for agitation associated with Alzheimer’s disease. AXS-07, a combination of meloxicam and rizatriptan for acute migraine, gained FDA approval in 2023. The company is also advancing AXS-12 for narcolepsy and idiopathic hypersomnia under FDA review, as well as AXS-14, a proprietary formulation of esreboxetine, targeting fibromyalgia and related chronic pain conditions. Founded in 2012 and headquartered in New York City, Axsome Therapeutics conducts its research and development activities primarily in the United States. The company’s leadership team is led by President and Chief Executive Officer Herriot Tabuteau, M.D., who brings extensive experience in neurologic and psychiatric drug development. Under his guidance, Axsome has advanced multiple clinical programs through crucial regulatory milestones and continues to collaborate with academic institutions and contract research organizations to support its growth strategy.View Axsome Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Quantum Earnings Week: Winners and Losers Are Finally EmergingMarketBeat Week in Review – 08/03 - 08/07Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in FocusDatadog’s Drop Says More About Expectations Than EarningsD-Wave's Quantum Breakthrough Couldn't Save QBTS From a Sell-OffAppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay BullishUber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside Upcoming Earnings Barrick Mining (8/10/2026)Simon Property Group (8/10/2026)SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026)BHP Group (8/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
